Escitalopram treatment in preschool children with anxiety disorders: Acase series;Anksiyete bozukluǧu olan okul öncesi çocuklarda essitalopram tedavisi: Bir olgu serisi

Klinik Psikofarmakoloji Bulteni

Volumn 22, Issue 3, 2012, Pages 262-267

  Coşkun, Murat ^a   Öztürk, Mücahit ^b   Zoroǧlu, Salih ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b Center for Psychiatric Research   (Turkey)

Author keywords

Anxiety disorder; Children; Escitalopram; Pharmacotherapy; Preschool

Indexed keywords

ESCITALOPRAM;

ANXIETY DISORDER; ARTICLE; ATTENTION DEFICIT DISORDER; BEHAVIOR DISORDER; CHILD; CHILD PSYCHIATRY; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GENDER IDENTITY DISORDER; GENERALIZED ANXIETY DISORDER; HUMAN; INCONTINENCE; MALE; OBSESSIVE COMPULSIVE DISORDER; OPPOSITIONAL DEFIANT DISORDER; POSTTRAUMATIC STRESS DISORDER; PRESCHOOL CHILD; SEPARATION ANXIETY; SOCIAL PHOBIA; TREATMENT RESPONSE;

EID: 84866853873     PISSN: 10177833     EISSN: 13029657     Source Type: Journal    
DOI: 10.5455/bcp.20120729101822     Document Type: Article

References (27)

1. Egger HL, Angold A. Common emotional and behavioral disorders in preschool children: Presentation, nosology, and epidemiology. J Child Psychol Psychiatry 2006;47 (3-4):313-37.
2. Gleason MM, Egger HL, Emslie GJ, Greenhill LL, Kowatch RA, Lieberman AF, et al. Psychopharmacological treatment for very young children: Contexts and guidelines. J Am Acad Child Adolesc Psychiatry 2007;46(12):1532-72.
3. Greenhill LL, Jensen PS, Abikoff H, Blumer JL, Deveaugh-Geiss J, Fisher C, et al. Developing strategies for psychopharmacological studies in preschool children. J Am Acad Child Adolesc Psychiatry 2003;42(4):406-14.
4. Wigal T, Greenhill L, Chuang S, McGough J, Vitiello B, Skrobala A, et al. Safety and tolerability of methylphenidate in preschool children with ADHD. J Am Acad Child Adolesc Psychiatry 2006;45(11):1294-303.
5. Ghuman JK, Arnold LE, Anthony BJ. Psychopharmacological and other treatments in preschool children with attention-deficit/ hyperactivity disorder: current evidence and practice. J Child Adolesc Psychopharmacol 2008;18(5):413-47.
6. Riddle MA. New Findings from the Preschoolers with Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS) J Child Adolesc Psychopharmacol 2007;17(5):543-6.
7. Luby J, Mrakotsky C, Stalets MM, Belden A, Heffelfinger A, Williams M, et al. Risperidone in preschool children with autistic spectrum disorders: an investigation of safety and efficacy. J Child Adolesc Psychopharmacol 2006;16(5):575-87.
8. Masi G, Cosenza A, Mucci M, Brovedani P. A 3-year naturalistic study of 53 preschool children with pervasive developmental disorders treated with risperidone. J Clin Psychiatry 2003;64(9):1039-47.
9. Coskun M, Zoroglu S, Ozturk M. Risperidone treatment in preschool children with disruptive behavior disorders: A chart review study. Klinik Psikofarmakoloji Bülteni-Bulletin Clinical Psychopharmacology 2011;21(1):33-41. (Turkish)
10. Coskun M, Zoroglu S. Efficacy and Safety of Fluoxetine in Preschool Children with Obsessive-Compulsive Disorder. J Child Adolesc Psychopharmacol 2009;19(3):297-300.
11. Oner O, Oner P. Psychopharmacology of pediatric obsessivecompulsive disorder: three case reports. J Psychopharmacol 2008;22(7):809-11.
12. Avci A, Diler RS, Tamam L. Fluoxetine treatment in a 2.5-year-old girl. J Am Acad Child Adolesc Psychiatry 1988;37(9):901-2.
13. Zuckerman ML, Vaughan BL, Whitney J, Dodds A, Yakhkind A, MacMillan C, et al. Tolerability of selective serotonin reuptake inhibitors in thirty-nine children under age seven: A retrospective chart review. J Child Adolesc Psychopharmacol 2007;17(2):165-74.
14. Liebowitz MR, Turner SM, Piacentini J, Beidel DC, Clarvit SR, Davies SO, et al. Fluoxetine in children and adolescents with OCD: A placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 2002;41(12):1431-38.
15. Birmaher B, Axelson DA, Monk K, Kalas C, Clark DB, Ehmann M, et al. Fluoxetine for the treatment of childhood anxiety disorders. J Am Acad Child Adolesc Psychiatry 2003;42(4):415-23.
16. The Research Unit on Pediatric Psychopharmacology Anxiety Study Group. Fluvoxamine for the treatment of anxiety disorders in children and adolescents. N Engl J Med 2001;344(17):1279-85.
17. Wagner KD, Berard R, Stein MB, Wetherhold E, Carpenter DJ, Perera P, et al. A multicenter, randomized, double-blind, placebocontrolled trial of paroxetine in children and adolescents with social anxiety disorder. Arch Gen Psychiatry 2004;61(11):1153-62.
18. Rynn MA, Siqueland L, Rickels K. Placebo-controlled trial of sertraline in the treatment of children with generalized anxiety disorder. Am J Psychiatry 2001;158(12):2008-14.
19. Seedat S, Stein DJ, Ziervogel C, Middleton T, Kaminer D, Emsley RA, et al. Comparison of response to selective serotonin reuptake inhibitor in children, adolescents, and adults with PTSD. J Child Adolesc Psychopharmacol 2002;12(1):37-46.
20. Yorbik O, Dikkatli S, Cansever A, Sohmen T. The efficacy of fluoxetine treatment in children and adolescents with posttraumatic stress disorder symptoms (Turkish). Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology 2001;11(4):251-6.
21. Cohen JA, Mannarino AP, Perel JM, Staron V. A pilot randomized trial of combined trauma-focused CBT and sertraline for childhood PTSD symptoms. J Am Acad Child Adolesc Psychiatry 2007;46(7):811-9.
22. Geller DA, Wagner KD, Emslie G, Murphy T, Carpenter DJ, Wetherhold E, et al. Paroxetine treatment in children and adolescents with obsessivecompulsive disorder: A randomized, multicenter, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 2004;43(11):1387-96.
23. Isolan L, Pheula G, Salum GA Jr, Oswald S, Rohde LA, Manfro GG. An open-label trial of escitalopram in children and adolescents with social anxiety disorder. J Child Adolesc Psychopharmacol 2007;17(6):751-60.
24. Ahn JH, Patkar AA. Escitalopram for the treatment of major depressive disorder in youth. Expert Opin Pharmacother 2011;12(14):2235-44.
25. Gualtieri CT, Johnson LG. Antidepressant Side Effects in Children and Adolescents. J Child Adolesc Psychopharmacol 2006;16 (1-2):147-57.
26. Safer DJ, Zito JM. Treatment-emergent adverse events from selective serotonin reuptake inhibitors by age group: Children versus adolescents. J Child Adolesc Psychopharmacol 2006;16(1-2):159-69.
27. Walkup J, Labellarte M. Complications of SSRI Treatment. J Child Adolesc Psychopharmacol 2001;11(1): 1-4.